NCT03891108View on ClinicalTrials.gov

A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2019

Primary Completion Date

July 29, 2019

Study Completion Date

July 29, 2019

Conditions
Heart Failure
Interventions
DRUG

BMS-986231 Formulation A

Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.

DRUG

BMS-986231 Formulation B

Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.

DRUG

BMS-986231 Formulation C

Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.

DRUG

BMS-986231 Formulation D

Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.

Trial Locations (1)

84124

PRA Health Sciences, Salt Lake City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY